Idioma:

Evidence for Clinical Safety, Efficacy, and Parent and Physician Perceptions of Levocetirizine for the Treatment of Children with Allergic Disease

Pampura, A.N. ; Papadopoulos, N.G. ; Špičák, V. ; Kurzawa, R.

International archives of allergy and immunology, 2011-07, Vol.155 (4), p.367-378 [Periódico revisado por pares]

Basel, Switzerland: Karger

Texto completo disponível

Citações Citado por

Enviar para

Título:
Evidence for Clinical Safety, Efficacy, and Parent and Physician Perceptions of Levocetirizine for the Treatment of Children with Allergic Disease
Autor: Pampura, A.N. ; Papadopoulos, N.G. ; Špičák, V. ; Kurzawa, R.
Assuntos: Adult ; Allergies ; Anti-Allergic Agents - adverse effects ; Anti-Allergic Agents - therapeutic use ; Attitude of Health Personnel ; Cetirizine - adverse effects ; Cetirizine - therapeutic use ; Child ; Child, Preschool ; Children & youth ; Chronic Disease ; Drug therapy ; Histamine ; Histamine H1 Antagonists, Non-Sedating - adverse effects ; Histamine H1 Antagonists, Non-Sedating - therapeutic use ; Humans ; Infant ; Original Paper ; Parents - psychology ; Pharmacology ; Physicians - psychology ; Randomized Controlled Trials as Topic ; Rhinitis, Allergic, Perennial - drug therapy ; Rhinitis, Allergic, Perennial - physiopathology ; Rhinitis, Allergic, Seasonal - drug therapy ; Rhinitis, Allergic, Seasonal - physiopathology ; Treatment Outcome ; Urticaria - drug therapy ; Urticaria - physiopathology
É parte de: International archives of allergy and immunology, 2011-07, Vol.155 (4), p.367-378
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) are highly burdensome diseases, which are increasing in prevalence, especially in the paediatric population. Despite the availability of a large number of medications for treatment of AR and CIU, their use in children has primarily been based on data obtained from a limited number of clinical trials in children and/or testing in adults. The H1-antihistamines have traditionally been used as first-line treatment for the relief of both AR and CIU symptoms in children. The first-generation H1-antihistamines are associated with marked adverse effects such as sedation, sleepiness/drowsiness as well as difficulties in learning and cognitive processing; thus, they are recommended for limited or discontinued use in children with AR or CIU. In contrast, second-generation H1-antihistamines are more adapted for the use in children with AR and CIU due to better safety profiles. However, only a limited number of trials with these agents have been conducted and generally, data from well-designed trials in children are lacking. Levocetirizine is one of the most extensively investigated H1-antihistamines for its pharmacologic properties, safety, efficacy as well as overall global satisfaction in children aged 2–12 years. Levocetirizine is the only H1-antihistamine launched in the 21st century shown to lack clinically relevant adverse effects on physical and psychomotor development or routine laboratory tests over a long-term period of 18 months in 1- to 3-year-old children predisposed to development of allergic disease. Available data suggest that levocetirizine is a suitable treatment option for AR and CIU in children aged 6 months to 12 years.
Editor: Basel, Switzerland: Karger
Idioma: Inglês;Russo

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Evidence for Clinical Safety, Efficacy, and Parent and Physician Perceptions of Levocetirizine for the Treatment of Children with Allergic Disease

Pampura, A.N. ; Papadopoulos, N.G. ; Špičák, V. ; Kurzawa, R.

Basel, Switzerland: Karger

Buscando em bases de dados remotas. Favor aguardar.